Definitions

Sorry, no definitions found. You may find more data at bcr-abl.

Etymologies

Sorry, no etymologies found.

Support

Help support Wordnik (and make this page ad-free) by adopting the word Bcr-Abl.

Examples

  • In many markets (where available), the Our Bcr-Abl franchise, consisting of Gleevec/Glivec and Tasigna, continued to grow strongly, reaching USD 1.3 billion (+12% cc) in the third quarter.

    Reuters: Press Release 2011

  • Nilotinib is a highly selective Bcr-Abl inhibitor approved for imatinib-resistant chronic myeloid leukemia (CML).

    Naturejobs - All Jobs F J Giles 2010

  • While Bristol-Myers Squibb Co's Sprycel and Novartis's Tasigna also aim to treat patients after unsuccessful Gleevec treatment, Omapro targets those who test positive for a specific genetic mutation known as the Bcr-Abl T315I mutation.

    FinanzNachrichten.de: Aktuelle Nachrichten 2010

  • While Bristol-Myers Squibb Co's Sprycel and Novartis's Tasigna also aim to treat patients after unsuccessful Gleevec treatment, Omapro targets those who test positive for a specific genetic mutation known as the Bcr-Abl T315I mutation.

    FinanzNachrichten.de: Aktuelle Nachrichten 2010

  • Almost all patients with CML have an abnormality known as the Philadelphia chromosome, which produces a protein called Bcr-Abl.

    WebWire | Recent Headlines 2010

  • ChemGenex Pharmaceuticals a complete response letter regarding its NDA for Omapro ™ for the treatment of adults with chronic myeloid leukemia (CML) who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.

    GEN News Highlights 2010

  • CML patients who have failed imatinib therapy and have the Bcr-Abl T315I mutation.

    The Earth Times Online Newspaper 2010

  • Tasigna is a potent and selective inhibitor of the Bcr-Abl protein that causes production of cancer cells in Ph+ CML [2], [3]

    WebWire | Recent Headlines 2010

  • ChemGenex 'application for Omapro is currently under review at the EMEA for CML patients who have failed imatinib therapy and have the Bcr-Abl T315I mutation.

    GEN News Highlights 2010

  • Bcr-Abl causes malignant white blood cells to proliferate [4].

    WebWire | Recent Headlines 2010

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.